$heff's $tation of $tocks & $olid DD

[Updowntruth]

$TRVN. TRV 027 actual Study Design and price action. Referenced from From the American College of Cardiology. JACC Heart Failure. (JACC.org)

Point 1. Rationale and Design of the BLAST-AHF Study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure).
http://heartfailure.onlinejacc.org/article.aspx?articleid=2107613#tab1

Point 2. Last year the study size was increased. The remaining enrollment was weighted towards the most promising dose seen that far based on interim analisys (5mg?)
http://www.trevenainc.com/news-details.php?id=100

Point 3. Look at any chart and look at the price action during 2015 (aug 31- Sep) upon release of their last positive Phase 2b study on one of their other candidate drugs.
reference news. 8/31/15 Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain.
http://www.trevenainc.com/news-details.php?id=100

Point 4. Why is the price here? Perhaps pull up a chart on any major index and compare the market's action $DJI- $COMPX (etc....) from mid-Dec 2015 thru Feb 2016 against the 1 Year chart of TRVN.

Point 5. What happened in Mar 2016 for the price drop?
Financial reports, sell the news. The financials where actually decreasing losses and plenty of cash. For the year ended December 31, 2015, the company incurred a net loss attributable to common stockholders of $50.5 million, or $1.15 per share, compared with a net loss attributable to common stockholders of $49.7 million, or $2.02 per share, for the comparable period in 2014.

Cash, cash equivalents and marketable securities were $172.6 million as of December 31, 2015, which the company expects to fund operations into 2018, including completion of oliceridine Phase 3 studies, NDA filing in the second half of 2017, and commercial launch preparations, as well as funding the continued progress of Trevena’s pipeline.
http://www.trevenainc.com/news-details.php?id=138

Point 6. and last... Which leads into a very defined wedge going into the next Phase 2b trial results on May 21st, in a late-breaking trials session scheduled for 2:15-3:45pm CEST on Saturday May 21. The presentation will be made by G. Michael Felker, M.D., Professor of Medicine at Duke University Medical Center and co-chair of the BLAST-AHF Steering Committee.
http://www.trevenainc.com/news-details.php?id=141

Disclosure: Interested in the company and the action.
Updowntruth